MedPath

Effect of Ayurveda panchakarma and rasayana therapy on gut microbiome in Diabetes patients

Not yet recruiting
Conditions
Type 2 diabetes mellitus without complications. Ayurveda Condition: MADHUMEHAH/KSHAUDRAMEHAH,
Registration Number
CTRI/2023/03/050816
Lead Sponsor
All India Institute of Ayurveda, CoE TRISUTRA CSIR IGIB
Brief Summary

Present studyis aiming to evaluate the efficacy of Virechana followed by Shilajatu rasayanain patients of Diabetes Mellitus type 2, on various parameters like Blood sugarfasting and post prandial and HbA1C, Apolipoprotein A1, Adiponectin, hs-CRP andAyurveda parameters like Deha bala, agni bala, chetas bala. Study is alsoaiming to see the gut microbiome alterations post Shodhana rasayana therapy in patients of Diabetes Mellitustype 2, which is a first ever attempt to study the same. Study also includesin-silico pathway analysis and ADR prediction of of present Rasayana drug

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Patients diagnosed with Diabetes Mellitus according to WHO criteria Subjects diagnosed for Madhemha based on general diagnostic criteria according to document of Protocol for Prevention and Control of Diabetes through Ayurveda, MoA, Page no 37, 2016 Recently diagnosed (0-5 years) patients who are not on OHA (both overweight/obese and normal BMI – ICMR Asian criteria #) Subjects of either gender aged more than 18 years, <60 yrs.
  • Willingness to consent to randomization.
Exclusion Criteria

Emergency cases of diabetes or under immediate consideration for hospitalization and Type 1 DM or Insulin-dependent Patient with inflammatory bowel disease Crohns disease or ulcerative colitis, chronic diarrhoea or malabsorption Hepatitis etc Patient with a history of other complications with DM Female patient who is pregnant, or breast feeding or is considering becoming pregnant during the study or for 6 months after the last dose of study medication Patients having known hypersensitivity to any of the proposed trial drug Currently under any other trial.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in Blood sugar fasting and post prandial and HbA1CChanges in Blood sugar fasting and post prandial and HbA1C -0,30, 60, 90th days | Changes seen Deha bala agni bala chetas bala- 0, 90th days | Alterations seen in biomarkers such as, Apolipoprotein A1, Adiponectin, hs-CRP-0th and 90th days | Potential pathways and mechanism of Shilajatu along with ADR
Changes seen Deha bala agni bala chetas balaChanges in Blood sugar fasting and post prandial and HbA1C -0,30, 60, 90th days | Changes seen Deha bala agni bala chetas bala- 0, 90th days | Alterations seen in biomarkers such as, Apolipoprotein A1, Adiponectin, hs-CRP-0th and 90th days | Potential pathways and mechanism of Shilajatu along with ADR
Alterations seen in biomarkers such as, Apolipoprotein A1, Adiponectin, hs-CRPChanges in Blood sugar fasting and post prandial and HbA1C -0,30, 60, 90th days | Changes seen Deha bala agni bala chetas bala- 0, 90th days | Alterations seen in biomarkers such as, Apolipoprotein A1, Adiponectin, hs-CRP-0th and 90th days | Potential pathways and mechanism of Shilajatu along with ADR
Potential pathways and mechanism of Shilajatu along with ADRChanges in Blood sugar fasting and post prandial and HbA1C -0,30, 60, 90th days | Changes seen Deha bala agni bala chetas bala- 0, 90th days | Alterations seen in biomarkers such as, Apolipoprotein A1, Adiponectin, hs-CRP-0th and 90th days | Potential pathways and mechanism of Shilajatu along with ADR
Secondary Outcome Measures
NameTimeMethod
Changes seen in Quality of Life in DMVariations seen in LDL, HDL, TC, HDL/TG Ratio, VLDL and TG

Trial Locations

Locations (1)

All India Institute of Ayurveda, Mathura road, Sarita Vihar, New Delhi

🇮🇳

South, DELHI, India

All India Institute of Ayurveda, Mathura road, Sarita Vihar, New Delhi
🇮🇳South, DELHI, India
Dr Mythri H S
Principal investigator
9448727127
drmythri.achar@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.